[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338536-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338536-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","brafv600e-mutation-and-high-expression-of-pdl1-in-rosai-dorfman-disease-case-report-and-review-of-the-literature","BRAFV600E mutation and high expression of PD‑L1 in Rosai-Dorfman disease - case report and review of the literature","","BRAF V600E mutations are common in histiocytic/dendritic cell neoplasms such as Erdheim-Chester disease and Langerhans cell histiocytosis, yet reports in Rosai-Dorfman disease are rare. This paper presents a case of BRAF V600E-mutated Rosai-Dorfman disease with generalized lymphadenopathy and documents PD-L1 expression in neoplastic histiocytes. A literature review evaluates the frequency, clinical impact, and diagnostic challenges of BRAF V600E in Rosai-Dorfman disease, including implications for targeted BRAF inhibition and checkpoint blockade therapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/brafv600e-mutation-and-high-expression-of-pdl1-in-rosai-dorfman-disease-case-report-and-review-of-the-literature/338536/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/brafv600e-mutation-and-high-expression-of-pdl1-in-rosai-dorfman-disease-case-report-and-review-of-the-literature/338536.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does the paper describe BRAF V600E in Rosai-Dorfman disease compared with other histiocytic/dendritic neoplasms?","Question",{"text":63,"@type":64},"BRAF V600E is frequently seen in Erdheim-Chester disease and Langerhans cell histiocytosis, but only a few Rosai-Dorfman disease cases have been reported. The review highlights that evidence in RDD remains limited.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What key findings were reported in the case presented in the paper?",{"text":68,"@type":64},"The case involves Rosai-Dorfman disease with generalized lymphadenopathy, harboring a BRAF V600E mutation. The authors also found PD-L1 expression in neoplastic histiocytes.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is distinguishing Rosai-Dorfman disease from other histiocytic/dendritic cell neoplasms emphasized?",{"text":72,"@type":64},"The document notes overlapping clinicopathological manifestations and immunophenotypic features across related neoplasms. It concludes that distinctive histopathological and immunophenotypic findings in the right clinical and radiologic context are necessary for accurate diagnosis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338536,1790198464,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Journal of Hematopathology (2024) 17:183–189 [https://doi.org/10.1007/s12308-024-0061](https://doi.org/10.1007/s12308-024-0061)1-9  \nBRAFV600E mutation and high expression of PD‑L1 in Rosai‑Dorfman disease: case report and review of the literature  \nFarnoush M. Moen1,2 · Mariam M. Youssef1 · Mihir Shukla3 · Mary Lynn Nierodzik3 · Marius E. Mayerhoefer4 · Christopher Park1  \nReceived: 14 November 2023 / Accepted: 1 November 2024 / Published online: 27 November 2024 © The Author(s) 2024  \nAbstract  \nBRAF V600E mutations are frequently found in histiocytic/dendritic cell neoplasms such as Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH), but few reports have also described BRAF mutations in Rosai-Dorfman disease (RDD), and even these cases may predominantly represent mixed histiocytosis. BRAF mutations have been studied in histiocytic/dendritic cell neoplasms and described to be associated with increased risk of relapse and long-term consequences, but few studies have examined BRAF V600E mutation in RDD, which is recognized as a neoplasm given the high frequency of MAPK pathway alterations. Here, we report a case of BRAF V600E-mutated RDD in a patient who presented with generalized lymphadenopathy. During our evaluation of this patient, we also found expression of PD-L1 in neoplastic histiocytes. During our review period, only few cases of RDD reported to harbor BRAF mutation or were evaluated for the expression of PDL1 by neoplastic cells. Given the potential challenges in distinguishing RDD from other histiocytic/ dendritic cell neoplasms, including mixed histiocytosis with similar clinicopathological manifestations, we will discuss the current state of knowledge regarding the frequency and clinical impact of BRAF V600E in RDD, as well as the role of BRAF mutations in RDD pathogenesis. Distinction of BRAF V600E mutated histiocytic/dendritic cell neoplasms requires consideration of distinctive histopathological and immunophenotypic findings in appropriate clinical and radiologic setting. Given the increasing use of BRAF inhibitors as well as checkpoint blockade inhibitors to treat a number of cancers, we will discuss the clinical implications of the presence of BRAF V600E mutation and PD-L1 expression in RDD.  \nKeywords Histiocytosis · Histiocytic/dendritic cell neoplasms · Rosai-Dorfman disease · Erdheim-Chester disease · BRAFV600E mutation · BRAF inhibitors · PDL1 inhibitors · Checkpoint blockade inhibitors · MAPK pathway  \nIntroduction  \nThe histiocytoses represent a heterogeneous group of abnormal proliferations of mature histiocytic/dendritic cells. In the 2016 revised classification of histiocytoses, Rosai-Dorfman disease (RDD, also known as massive lymphadenopathy  \n* Farnoush M. Moen  \n[fmmoen@ucdavis.edu](fmmoen@ucdavis.edu); [fmmoenmd@gmail.com](fmmoenmd@gmail.com)  \n1 Department of Pathology, NYU Langone Health, NYU Grossman School of Medicine, New York, NY, USA  \n2 Department of Pathology and Laboratory Medicine, UC Davis, Davis, CA, USA  \n3 Department of Medicine, NYU Langone Health, NYU Grossman School of Medicine, New York, NY, USA  \n4 Department of Radiology, NYU Langone Health, NYU Grossman School of Medicine, New York, NY, USA  \nwith sinus histiocytosis), was placed in the “R” group, which can be distinguished from “L” group (Langerhans) based on the absence of CD1a and CD207 expression. RDD can be subclassified based on clinical features and includes a familial type due to FAS deficiency, classic (nodal), extranodal, immune disease-associated, or neoplasia-associated forms that occur post-leukemia or post-lymphoma, or in association with other histiocytic neoplasms [1] . Recent studies have identified mutations involving the MAPK/ERK pathway in 30–50% of RDD cases, supporting the neoplastic nature of RDD histiocytes [2–4] . The 5th edition of the WHO Classification of Hematolymphoid Tumors subcategorizes the dendritic cell neoplasms under the spectrum of histiocytic/dendritic cell neoplasm","cbCaihEK3A32GYlk","https://ap.wps.com/l/cbCaihEK3A32GYlk","pdf",877142,"English","# Abstract\n# Introduction\n# Case presentation","[{\"question\":\"How does the paper describe BRAF V600E in Rosai-Dorfman disease compared with other histiocytic/dendritic neoplasms?\",\"answer\":\"BRAF V600E is frequently seen in Erdheim-Chester disease and Langerhans cell histiocytosis, but only a few Rosai-Dorfman disease cases have been reported. The review highlights that evidence in RDD remains limited.\"},{\"question\":\"What key findings were reported in the case presented in the paper?\",\"answer\":\"The case involves Rosai-Dorfman disease with generalized lymphadenopathy, harboring a BRAF V600E mutation. The authors also found PD-L1 expression in neoplastic histiocytes.\"},{\"question\":\"Why is distinguishing Rosai-Dorfman disease from other histiocytic/dendritic cell neoplasms emphasized?\",\"answer\":\"The document notes overlapping clinicopathological manifestations and immunophenotypic features across related neoplasms. It concludes that distinctive histopathological and immunophenotypic findings in the right clinical and radiologic context are necessary for accurate diagnosis.\"}]","BRAFV600E mutation and high expression of PD‑L1 in Rosai-Dorfman disease - case report and review of the literature | PDF",1790024096,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bcbacee273e1bf690018f208cd7ccbc5.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7f0267111cdaeb9cf837cf561c5956d.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51577edbf33cf52a674797314e477346.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/afd5243cdcbc6b28dbe7b5e47c579a6e.webp",980,1301]